PT - JOURNAL ARTICLE AU - Hamilton, Fergus AU - Lee, Todd C AU - Butler-Laporte, Guillaume TI - Instrumental variable analysis: choice of control variables is critical and can lead to biased results AID - 10.1101/2024.07.11.24310262 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.11.24310262 4099 - http://medrxiv.org/content/early/2024/07/11/2024.07.11.24310262.short 4100 - http://medrxiv.org/content/early/2024/07/11/2024.07.11.24310262.full AB - Instrumental variable (IV) analysis is a widely used technique in econometrics to estimate causal effects in the presence of confounding. A recent application of this technique was used in a high-profile analysis in JAMA Internal Medicine to estimate the effect of cefepime, a broad-spectrum antibiotic, on mortality in severe infection. There has been ongoing concern that piperacillin-tazobactam, another broad-spectrum antibiotic with greater anaerobic activity might be inferior to cefepime, however this has not been shown in randomized controlled trials. The authors used an international shortage of piperacillin-tazobactam as an instrument, as during this shortage period, cefepime was used as an alternative. The authors report a strong mortality effect (5% absolute increase) with piperacillin-tazobactam. In this paper, we closely examine this estimate and find it is likely conditional on inclusion of a control variable (metronidazole usage). Inclusion of this variable is highly likely to lead to collider bias, which we show via simulation. We then generate estimates unadjusted for metronidazole which are much closer to the null and may represent residual confounding or confounding by indication. We highlight the ongoing challenge of collider bias in empirical IV analyses and the potential for large biases to occur. We finally suggest the authors consider including these unadjusted estimates in their manuscript, as the large increase in mortality reported with piperacillin-tazobactam is unlikely to be true.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFHs time was funded by the NIHR Clinical Lectureship scheme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data presented is available, or in the supplement.